HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) w

Top analysts changed outlook on top names. See analyst ratings page for all changes.

Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:R

Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI),

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday&#39

SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a c

~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietar

SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a cl

SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeut

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the a

- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of ob

SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeut

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therape

Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) w

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.07) per share which missed th

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-valu

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therape

Rani Therapeutics (NASDAQ: RANI - Get Free Report) and Milestone Pharmaceuticals (NASDAQ: MIST - Get

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therape

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report) has earned an average recommendati

SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) w

PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen Co., Ltd.

- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight lo

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report)'s share price fell 2.2% during mid

Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, comp

Biotech stocks have trailed the broader market this year, but more names are starting to show streng

HC Wainwright & Co. analyst Brandon Folkes assumes Rani Therapeutics Hldgs (NASDAQ:RANI) with

Maxim Group analyst Michael Okunewitch maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy